Here is the article from here about the need to get people mRNA vaccines in the mid-term (translated to English). Interesting read. Of course the government will not listen.

Google Translate

I am not very familiar with this publication. It's a British current events/politics magazine. They brought up something I have not heard elsewhere and found interesting:

"As for Sinovac, results have been all over the place. Brazilian trials at first suggested an efficacy against symptomatic illness of 78 per cent — hastily downgraded to just 50.4 per cent when mild cases were added. That is only just over the 50 per cent threshold that the WHO, and many countries, demand for approval. Other trials have produced better outcomes: interim results from a Turkish study claimed 91 per cent efficacy and a study involving Indonesian healthcare workers 65 per cent.

Why are these results so different? One possibility is that different trials are using different standards to define symptomatic disease. Another is that production of the Sinovac vaccine itself is not constant: that different batches have very different results. That is one problem with producing dead-virus vaccines: the process of inactivating the live virus, either chemically or through the application of heat, can change the way the body reacts to it. But with a lack of good data from the company itself it is hard to tell. The biggest blot against Sinovac remains the real-world data from Chile."

https://www.spectator.co.uk/article/...cine-programme

Lack of good data from the manufacturer plus poor production controls. It 's not like China is known for quality control. Maybe that's part of the problem. Maybe it's a role of the dice if you are given a dose from a good batch or not.